Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 7618

Last year information was released concerning rejuvenation of the thymus which resulted in a reversal of the epigenetic clock an average of 2.5 years in a small trial of 9 people costing $10,000 per person. You can get this done too. A company has formed called Intervene Immune which will take on volunteers for the process. It is not funded so you would have to pay out pf pocket though eventually the cost may come down and they can provide financing. You do not have to travel to California to get this done. Cost prohibits me, and I may or may not be eligible as I have IBS though that is not on the exclusion list. I emailed them concerning all this which is how I got the information.

Intro page

https://www.surveymonkey.com/r/TRIIMX

The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.

Continue reading “Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial” | >

BYD, one of the world’s largest electric bus manufacturer, boasted recently that its zero-emission buses already covered more than 13 million miles (21 million km) in the U.S.

The buses sold in North America are made in Lancaster, California, where local transit agency — the Antelope Valley Transit Authority (AVTA) — just crossed the 3-million-mile mark of zero-emission operations using BYD buses.

Overall, the company sold buses to more than 50 customers across the country. According to BYD, the total mileage translated into:

Read more | >

NASA’s Perseverance Mars rover launched from Cape Canaveral, Florida, on 30 July, carrying a host of cutting-edge technology including high-definition video equipment and the first interplanetary helicopter.

Many of the tools are designed as experimental steps toward human exploration of the red planet. Crucially, Perseverance is equipped with a device called the Mars Oxygen In-Situ Resource Utilization Experiment, or MOXIE: an attempt to produce oxygen on a planet where it makes up less than 0.2 percent of the atmosphere.

Oxygen is a cumbersome payload on space missions. It takes up a lot of room, and it’s very unlikely that astronauts could bring enough of it to Mars for humans to breathe there, let alone to fuel spaceships for the long journey home.

Read more | >

Hereditary hearing loss is one of the most common disabilities among newborns, affecting approximately 1 in 1000 live-born babies. Most forms of hereditary hearing loss are nonsyndromic; 80% of affected newborns have hearing loss that is inherited in an autosomal recessive pattern, and in the remaining 20%, inheritance shows a dominant pattern.

Many forms of hereditary hearing loss are caused by mutations in genes that affect the formation and function of cochlear hair cells — highly specialized sensory cells that play an important role in the detection and processing of sound. The hair cell has bundles of hair-like projections, called stereocilia, on its apical surface ( Fig. 1 ). The deflection of these bundles by sound results in the opening of mechanotransduction ion channels, which are located at the tips of the stereocilia, and consequently, in the depolarization of the hair-cell membrane. Mutations that affect the protein transmembrane channel-like 1 (TMC1), an integral component of the mechanotransduction complex, cause autosomal dominant and autosomal recessive forms of hearing loss. Correction of the dominant form of hearing loss in a mouse model of Tmc1 (termed “Beethoven”) was recently reported by Gao and colleagues.

An external file that holds a picture, illustration, etc. Object name is nihms-1017746-f0001.jpg

Read more | >

Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up. This could decrease the mortality of patients affected by COVID-19, according to the peer-reviewed journal PHAGE: Therapy, Applications, and Research.

“The bacterial growth rate could potentially be reduced by the aerosol application of natural bacteriophages. These prey on the main species of bacteria known to cause respiratory failure,” says Marcin Wojewodzic, PhD, University of Birmingham (U.K.). Decreasing bacterial growth would also give the body more time to produce protective antibodies against the disease-causing coronavirus.

Used correctly, phages have an advantage here of being able to very specifically target the bacteria that cause secondary infections. They would remove the problematic bacterium but leave an otherwise fragile microbiome intact.” Martha Clokie, PhD, Editor-in-Chief of PHAGE and Professor of Microbiology, University of Leicester (U.K.)

The pandemic of the coronavirus disease (Covid-19) has caused the death of at least 270,000 people as of the 8th of May 2020. This work stresses the potential role of bacteriophages to decrease the mortality rate of patients infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. The indirect cause of mortality in Covid-19 is miscommunication between the innate and adaptive immune systems, resulting in a failure to produce effective antibodies against the virus on time. Although further research is urgently needed, secondary bacterial infections in the respiratory system could potentially contribute to the high mortality rate observed among the elderly due to Covid-19. If bacterial growth, together with delayed production of antibodies, is a significant contributing factor to Covid-19’s mortality rate, then the additional time needed for the human body’s adaptive immune system to produce specific antibodies could be gained by reducing the bacterial growth rate in the respiratory system of a patient. Independently of that, the administration of synthetic antibodies against SARS-CoV-2 viruses could potentially decrease the viral load. The decrease of bacterial growth and the covalent binding of synthetic antibodies to viruses should further diminish the production of inflammatory fluids in the lungs of patients (the indirect cause of death). Although the first goal could potentially be achieved by antibiotics, I argue that other methods may be more effective or could be used together with antibiotics to decrease the growth rate of bacteria, and that respective clinical trials should be launched.

Continue reading “Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19)” | >

Superinfections — a common complication in which a secondary bacterial infection occurs on top of the primary viral infection — are also to blame.

Early evidence (Trusted Source) suggests that about 50 percent of people who’ve died from COVID-19 also had a secondary bacterial or fungal infection, some of which were resistant to antibiotics.

First is a condition called ventilator-associated pneumonia (Trusted Source), a lung infection that develops when harmful germs get into a person’s lungs via the part of the ventilator that goes through the throat.

Nearly half of patients who’ve died from COVID-19 had a secondary bacterial infection. Sometimes, these secondary infections are resistant to antibiotics and antifungals, making them difficult and potentially impossible to treat.

Continue reading “Drug-Resistant Bacteria Hidden Danger for People with COVID-19” | >

50% of people who die of covid19 have bacterial co-infections. Procalcitonin (PCT) tests may be needed to predict who will have severe infections, and how to respond with adaquate treatment. Clearly the wrong testing is being done. People need 3 tests for covid. People need antigen tests, antibody tests, and Procalcitonin (PCT) tests to see the severity of sickness a person will have.

Procalcitonin (PCT) is a widely used biomarker to assess the risk of bacterial infection and disease progression. In patients with bacterial sepsis, suspected or confirmed lower respiratory tract infections, including community-acquired pneumonia, acute bronchitis and acute exacerbations of COPD, PCT can be a useful decision-making tool for antibiotic therapy (Schuetz et al. 2018). In addition, early evidence suggests that PCT may also be a valuable tool in identifying COVID-19 patients who may be at risk for bacterial co-infection.

Procalcitonin is widely used to assess the risk of bacterial infection and disease progression. Can it be an additional tool to identify COVID-19 patients at risk of severe disease?

Read more | >